Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT02811861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Study identification
- NCT ID
- NCT02811861
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,069 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2016 (Actual)
- Primary completion
- Aug 28, 2020 (Actual)
- Completion
- Mar 31, 2027 (Estimated)
- Last update posted
- Feb 23, 2026
2016 – 2027
United States locations
- U.S. sites
- 35
- U.S. states
- 16
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford School of Medicine | Stanford | California | 94305-5826 | — |
| Boca Raton Community Hospital | Boca Raton | Florida | 33486 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33136 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Florida Cancer Specialists ( North Region) | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Joliet Oncology - Hematology Associates | Joliet | Illinois | 60435 | — |
| Healthcare Research Network III, LLC | Tinley Park | Illinois | 60487 | — |
| Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC | Overland Park | Kansas | 66209 | — |
| Cotton-Oneil Clinical Research Center | Topeka | Kansas | 66604 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Associates in Oncology & Hematology, PC | Bethesda | Maryland | 20817 | — |
| Massachusetts General Hospital- MGH | Boston | Massachusetts | 02214 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| GU Research Network | Omaha | Nebraska | 68130 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Hackensack Medical Center | Hackensack | New Jersey | 07601 | — |
| Rosewell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Broome Oncology | Johnson City | New York | 13790 | — |
| Weill Cornell Medical College New York Presbyterian Hospital | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Mission Hospital_ Cancer Care of Western North Carolina | Asheville | North Carolina | 28801 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29412 | — |
| SCRI - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology, P.A. | Dallas | Texas | 75231 | — |
| Texas Oncology PA | Fort Worth | Texas | 76104 | — |
| Texas Oncology PA - McAllen | McAllen | Texas | 78503 | — |
| Texas Oncology PA - Paris | Paris | Texas | 75460 | — |
| USOR Texas Oncology | The Woodlands | Texas | 77380 | — |
| Texas Oncology PA - Tyler | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 148 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02811861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02811861 live on ClinicalTrials.gov.